Prestigious science journal retracts findings on ill-effects of GM maize

Author's supporter plans to publish study in another journal

Image
Sanjeeb Mukherjee New Delhi
Last Updated : Dec 03 2013 | 3:44 PM IST
A year-after the prestigious ‘Food and Chemical Toxicology’ Journal published a study which concluded  that biotech maize and herbicides can cause “severe adverse health effects including mammary tumours and kidney and liver damage, leading to premature death,” the journal has announced retracting the piece for want of sufficient data.
 
The study, which was conducted by a team of researchers from the University of Caen (France) led by Gilles-Eric Seralini, had concluded that biotech maize and herbicide can be severely detrimental to human consumption. 
 
The team had based their analysis on a series of studies conducted on rats fed with biotech maize. However,   many pro-GM groups had severely criticized the analysis on the grounds of insufficient evidence. 
 
The Journal, which is one of the most prestigious publications, on science constituted a panel to look into the data published in the study and found that there were questions on the quality of the data submitted and hence recommended its retraction. 
Seralini, meanwhile, has planned to sue the journal and one of his supporter plans to publish another article in Statistical Models and Methods for Reliability and Survival Analysis, sometime in December 2013/January 2014 edition in support of Seralini’s findings. 
 
The Food and Chemical Toxicology is a peer-reviewed scientific journal covering issues related to food safety, chemical safety and other aspects of consumer product safety. It is published by Elsevier and was established in 1963. Elsevier is the publisher of well-known scientific journals like Lancet and Cell. 
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 03 2013 | 3:16 PM IST

Next Story